Comparative Pharmacology
Head-to-head clinical analysis: NORGESTREL AND ETHINYL ESTRADIOL versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTREL AND ETHINYL ESTRADIOL versus STILPHOSTROL.
NORGESTREL AND ETHINYL ESTRADIOL vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norgestrel is a progestogen that suppresses gonadotropin secretion, primarily LH, inhibiting ovulation and altering cervical mucus to impede sperm penetration. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides negative feedback on gonadotropin release, contributing to contraceptive efficacy.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily, taken at the same time each day.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Norgestrel: terminal half-life ~45 hours (range 24–50 h), supporting once-daily dosing; Ethinyl estradiol: terminal half-life ~17 hours (range 10–24 h).
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Norgestrel: 45% renal, 32% fecal as metabolites; Ethinyl estradiol: 40% renal, 60% fecal as glucuronide and sulfate conjugates.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen